Second- and third-generation ALK inhibitors for non-small cell lung cancer

Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jingjing, Savooji, John, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782349/
https://www.ncbi.nlm.nih.gov/pubmed/26951079
http://dx.doi.org/10.1186/s13045-016-0251-8
_version_ 1782419935878709248
author Wu, Jingjing
Savooji, John
Liu, Delong
author_facet Wu, Jingjing
Savooji, John
Liu, Delong
author_sort Wu, Jingjing
collection PubMed
description Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib. This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib.
format Online
Article
Text
id pubmed-4782349
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47823492016-03-09 Second- and third-generation ALK inhibitors for non-small cell lung cancer Wu, Jingjing Savooji, John Liu, Delong J Hematol Oncol Review Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib. This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib. BioMed Central 2016-03-08 /pmc/articles/PMC4782349/ /pubmed/26951079 http://dx.doi.org/10.1186/s13045-016-0251-8 Text en © Wu et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Wu, Jingjing
Savooji, John
Liu, Delong
Second- and third-generation ALK inhibitors for non-small cell lung cancer
title Second- and third-generation ALK inhibitors for non-small cell lung cancer
title_full Second- and third-generation ALK inhibitors for non-small cell lung cancer
title_fullStr Second- and third-generation ALK inhibitors for non-small cell lung cancer
title_full_unstemmed Second- and third-generation ALK inhibitors for non-small cell lung cancer
title_short Second- and third-generation ALK inhibitors for non-small cell lung cancer
title_sort second- and third-generation alk inhibitors for non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782349/
https://www.ncbi.nlm.nih.gov/pubmed/26951079
http://dx.doi.org/10.1186/s13045-016-0251-8
work_keys_str_mv AT wujingjing secondandthirdgenerationalkinhibitorsfornonsmallcelllungcancer
AT savoojijohn secondandthirdgenerationalkinhibitorsfornonsmallcelllungcancer
AT liudelong secondandthirdgenerationalkinhibitorsfornonsmallcelllungcancer

Ejemplares similares